Derek R. Clements
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Derek R. Clements has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Juliana Idoyaga
Department of Pharmacology University of California San Diego School of Medicine La Jolla California USA
3 shared publications - Andres Gottfried-Blackmore
Department of Pharmacology University of California San Diego School of Medicine La Jolla California USA
2 shared publications - David Seong
Department of Anesthesiology, Perioperative, and Pain Medicine, Stanford School of Medicine, Stanford, CA, USA
2 shared publications - Edward Elliot Graves
Department of Radiation Oncology, Stanford University, Stanford, CA 94305, USA
2 shared publications - Matthias Mack
Department of Nephrology, University Hospital Regensburg, Regensburg, Germany
2 shared publications - Sanjana Saravanan
DNA Motors Group, MRC Laboratory of Medical Sciences, London W12 0HS, UK
2 shared publications
Latest Publications
- Open Access
- 27 March 2025
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 222 (6)
CD301b+ monocyte-derived dendritic cells mediate resistance to radiotherapy
Monocytes infiltrating tumors acquire various states that distinctly impact cancer treatment. Here, we show that resistance of tumors to radiotherapy (RT) is controlled by the accumulation of monocyte-derived dendritic cells (moDCs). These moDCs are characterized by the expression of CD301b and have a superior capacity to generate regulatory T cells (Tregs). Accordingly, moDC depletion limits Treg generation and improves the therapeutic outcome of RT. Mechanistically, we demonstrate that granulocyte–macrophage colony-stimulating factor (GM-CSF) derived from radioresistant tumor cells following RT is necessary for the accumulation of moDCs. Our results unravel the immunosuppressive function of moDCs and identify GM-CSF as an immunotherapeutic target during RT.
- 27 March 2025
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 222 (6)
Open AccessCD301b+ monocyte-derived dendritic cells mediate resistance to radiotherapy
Monocytes infiltrating tumors acquire various states that distinctly impact cancer treatment. Here, we show that resistance of tumors to radiotherapy (RT) is controlled by the accumulation of monocyte-derived dendritic cells (moDCs). These moDCs are characterized by the expression of CD301b and have a superior capacity to generate regulatory T cells (Tregs). Accordingly, moDC depletion limits Treg generation and improves the therapeutic outcome of RT. Mechanistically, we demonstrate that granulocyte–macrophage colony-stimulating factor (GM-CSF) derived from radioresistant tumor cells following RT is necessary for the accumulation of moDCs. Our results unravel the immunosuppressive function of moDCs and identify GM-CSF as an immunotherapeutic target during RT.
- Open Access
- 30 June 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 8 (84) , eadd7446
Rapid recruitment and IFN-I–mediated activation of monocytes dictate focal radiotherapy efficacy
The recruitment of monocytes and their differentiation into immunosuppressive cells is associated with the low efficacy of preclinical nonconformal radiotherapy (RT) for tumors. However, nonconformal RT (non-CRT) does not mimic clinical practice, and little is known about the role of monocytes after RT modes used in patients, such as conformal RT (CRT). Here, we investigated the acute immune response induced by after CRT. Contrary to non-CRT approaches, we found that CRT induces a rapid and robust recruitment of monocytes to the tumor that minimally differentiate into tumor-associated macrophages or dendritic cells but instead up-regulate major histocompatibility complex II and costimulatory molecules. We found that these large numbers of infiltrating monocytes are responsible for activating effector polyfunctional CD8 + tumor-infiltrating lymphocytes that reduce tumor burden. Mechanistically, we show that monocyte-derived type I interferon is pivotal in promoting monocyte accumulation and immunostimulatory function in a positive feedback loop. We also demonstrate that monocyte accumulation in the tumor microenvironment is hindered when RT inadvertently affects healthy tissues, as occurs in non-CRT. Our results unravel the immunostimulatory function of monocytes during clinically relevant modes of RT and demonstrate that limiting the exposure of healthy tissues to radiation has a positive therapeutic effect on the overall antitumor immune response.
- 30 June 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 8 (84) , eadd7446
Open AccessRapid recruitment and IFN-I–mediated activation of monocytes dictate focal radiotherapy efficacy
The recruitment of monocytes and their differentiation into immunosuppressive cells is associated with the low efficacy of preclinical nonconformal radiotherapy (RT) for tumors. However, nonconformal RT (non-CRT) does not mimic clinical practice, and little is known about the role of monocytes after RT modes used in patients, such as conformal RT (CRT). Here, we investigated the acute immune response induced by after CRT. Contrary to non-CRT approaches, we found that CRT induces a rapid and robust recruitment of monocytes to the tumor that minimally differentiate into tumor-associated macrophages or dendritic cells but instead up-regulate major histocompatibility complex II and costimulatory molecules. We found that these large numbers of infiltrating monocytes are responsible for activating effector polyfunctional CD8 + tumor-infiltrating lymphocytes that reduce tumor burden. Mechanistically, we show that monocyte-derived type I interferon is pivotal in promoting monocyte accumulation and immunostimulatory function in a positive feedback loop. We also demonstrate that monocyte accumulation in the tumor microenvironment is hindered when RT inadvertently affects healthy tissues, as occurs in non-CRT. Our results unravel the immunostimulatory function of monocytes during clinically relevant modes of RT and demonstrate that limiting the exposure of healthy tissues to radiation has a positive therapeutic effect on the overall antitumor immune response.
- Open Access
- 7 September 2021
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 218 (10)
Alveolar macrophages and epithelial cells: The art of living together
In this issue of JEM, Gschwend et al. (2021. J. Exp. Med.https://doi.org/10.1084/jem.20210745) reveal the indispensable role of alveolar epithelial cells type 2 in controlling the density of alveolar macrophages. This study highlights the intricate crosstalk that lung stroma and macrophages undergo to maintain homeostasis.
- 7 September 2021
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 218 (10)
Open AccessAlveolar macrophages and epithelial cells: The art of living together
In this issue of JEM, Gschwend et al. (2021. J. Exp. Med.https://doi.org/10.1084/jem.20210745) reveal the indispensable role of alveolar epithelial cells type 2 in controlling the density of alveolar macrophages. This study highlights the intricate crosstalk that lung stroma and macrophages undergo to maintain homeostasis.